Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Mark Lubberink"'
Autor:
Mark Lubberink, Adriaan A. Lammertsma, Astrid A.M. van der Veldt, Gert Luurtsema, N. Harry Hendrikse
Publikováno v:
van der Veldt, A A M, Luurtsema, G, Lubberink, J M, Lammertsma, A A & Hendrikse, N H 2008, ' Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance ', Current Pharmaceutical Design, vol. 14, no. 28, pp. 2914-2931 . https://doi.org/10.2174/138161208786404344
Current Pharmaceutical Design, 14(28), 2914-2931. Bentham Science Publishers B.V.
Current Pharmaceutical Design, 14(28), 2914-2931. Bentham Science Publishers B.V.
Tumour resistance to anticancer agents remains a challenge in oncological practice, because it results in exposure to toxicities, unnecessary costs and, most importantly, delay of a potentially more effective treatment. Drug uptake by tumours may be